Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588025 | 0.87 | SIGMAR1 (0.47) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL6263887 | 0.85 | SIGMAR1 (0.52) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL5242533 | 0.85 | SLC6A4 (0.53) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL5230749 | 0.84 | SIGMAR1 (0.44) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL8971103 | 0.84 | MAOA (0.51) | SIGMAR1DRD2HTR1ADRD4DRD3 | |
| SCHEMBL23063982 | 0.83 | SIGMAR1 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL8984029 | 0.83 | SIGMAR1 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL5154581 | 0.83 | SIGMAR1 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| Hydrochloric Acid SCHEMBL23882203 | 0.83 | DRD2 (0.50) | SIGMAR1DRD2HTR1AHTR2AHTT | |
| SCHEMBL8427500 | 0.83 | CCR3 (0.44) | SIGMAR1DRD2HTR1AHTR2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005076749-A2 | A NOVEL PROCESS FOR THE PREPARATION OF 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE | JUBILANT ORGANOSYS LIMITED (IN) | 2005-08-25 | — | — | WO | claimed |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250195484-A1 | CEREBLON LIGANDS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4554948-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Regents of the University of Michigan (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025098503-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2025026283-A1 | COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF | 甘李药业股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-1999002156-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0880500-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| CN-1199397-A | Pyrimidin derivatives | HOFFMANN LA ROCHE (CH) | 1998-11-18 | — | — | CN | disclosed |
| EP-0873317-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5700809-A | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1997-12-23 | — | — | US | disclosed |
| US-5688798-A | PSYCHOTIC ILLNESS SUCH AS SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997030031-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997013759-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-17 | — | — | WO | disclosed |
| EP-0687267-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | SIGMAR1 3821/4885DRD2 1575/4885HTR1A 3208/4885 |
| US-20250195484-A1 | CEREBLON LIGANDS AND USES THEREOF | CRBN, CDR2, CHLSN | SIGMAR1 2415/4885DRD2 3102/4885HTR1A 2926/4885 |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | SIGMAR1 134/4885DRD2 368/4885HTR1A 380/4885 |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | SIGMAR1 96/4885DRD2 495/4885HTR1A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.